Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Importance Clinical outcomes after curative treatment of resectable pancreatic ductal
adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of …

This manuscript is the result of the North American Neuroendocrine Tumor Society
consensus conference on the surgical management of pancreatic neuroendocrine tumors …

Objective: This study was performed to determine whether neoadjuvant treatment increases
survival in patients with BRPC. Summary Background Data: Despite many promising …

Pancreatic cancer is a growing source of cancer related death, yet has poor survival rates
which have not improved in the last few decades. Its high mortality rate is attributed to …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

This statement was developed to promote international consensus on the definition of
borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by …

A recent study estimating cancer epidemiology in 2014 (within Europe) showed that
pancreatic cancer was the fourth most fatal cancer in men after lung, colorectal, and prostate …